ALLERGAN'S "NEVER ENDING" SEARCH FOR CONTACT LENS MANUFACTURER CONTINUES
Allergan remains committed to acquiring a contact lens manufacturer to penetrate what it estimates as a $1 bil. 1986 market, after failed attempts in recent years with Hydron and American Optical. "We have our never ending search for a contact lens company," Allergan President William Shepherd told analysts Dec. 16 at SmithKline Beckman's biannual analysts meeting in Philadelphia. "In 1984 we tried to buy one; in 1985 we tried to buy one . . . but we continue [to try]." In its recent "Dutch auction" filing, SmithKline reported that it is in negotiations for an acquisition (or acquisitions) valued at $250 mil. A contact lens business would be an obvious choice given the company's continued interest in expanding into that market. Asked why the company has been unable to succeed in acquiring a contact lens manufacturer, Shepherd replied that "the honest answer is they always want more than you're willing to pay." He said that the Hydron deal fell through when its earnings slipped following commencement of the CooperVision/Bausch & Lomb "bidding war" in 1983. The other announced merger effort, with American Optical, was scrappe by the Federal Trade Commission for competitive reasons. Allergan sees a $1 bil. market for contact lenses in 1986 growing at 8-10% through 1990. In spite of its lack of presence in the contact lens manufacturing field, Allergan has built an eye care business that will climb past $400 mil. in 1986. Allergan indicated it had worldwide sales of approximately $47.6 mil. in diagnostic instruments, $51.8 mil. in IOLs, $15 mil. in surgical equipment, $159.3 mil. in contact lens care products, and $138 mil. in ophthalmic drugs. To sell its products, Allergan has been rapidly expanding its sales force. At the end of 1986 there were 250 sales reps in the U.S., up from 109 two years ago.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth